Design Therapeutics (DSGN) Research & Development (2020 - 2026)
Design Therapeutics recorded quarterly Research & Development of $14.4 million in Q1 2026, up 131.53% quarter-over-quarter from -$45.6 million in Q4 2025, and down 6.49% year-over-year from $15.4 million in Q1 2025.
Design Therapeutics' Research & Development history runs 7 years deep, the most recent figure standing at $14.4 million for Q1 2026.
- In Q1 2026, Research & Development fell 6.49% year-over-year to $14.4 million; the TTM figure through Mar 2026 stood at -$898000.0 (down 101.8% YoY), while the FY2025 annual figure was $100000.0, down 99.77% from the prior year.
- Research & Development came in at $14.4 million for Q1 2026 at Design Therapeutics, up from -$45.6 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $17.1 million in Q2 2023 to a low of -$45.6 million in Q4 2025.
- A 5-year average of $9.7 million and a median of $13.3 million in 2023 frame the typical range for Research & Development.
- Across the five-year window, Research & Development surged 126.04% in 2022 and plunged 475.13% in 2025, its largest moves.
- Design Therapeutics' Research & Development stood at $14.3 million in 2022, then fell by 22.75% to $11.0 million in 2023, then gained by 10.4% to $12.2 million in 2024, then slumped by 475.13% to -$45.6 million in 2025, then surged by 131.53% to $14.4 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $14.4 million, -$45.6 million, and $14.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Design Therapeutics | 640.15 Mn | 417.32 Mn | - | 14.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.38 Mn |
| Dec 31, 2025 | -45.60 Mn |
| Sep 30, 2025 | 14.59 Mn |
| Jun 30, 2025 | 15.74 Mn |
| Mar 31, 2025 | 15.38 Mn |
| Dec 31, 2024 | 12.16 Mn |
| Sep 30, 2024 | 11.88 Mn |
| Jun 30, 2024 | 10.52 Mn |
| Mar 31, 2024 | 9.80 Mn |
| Dec 31, 2023 | 11.01 Mn |
| Sep 30, 2023 | 13.26 Mn |
| Jun 30, 2023 | 17.06 Mn |
| Mar 31, 2023 | 15.73 Mn |
| Dec 31, 2022 | 14.26 Mn |
| Sep 30, 2022 | 14.30 Mn |
| Jun 30, 2022 | 11.30 Mn |
| Mar 31, 2022 | 8.76 Mn |
| Dec 31, 2021 | 7.34 Mn |
| Sep 30, 2021 | 8.54 Mn |
| Jun 30, 2021 | 5.03 Mn |
| Mar 31, 2021 | 3.88 Mn |
| Dec 31, 2020 | 2.71 Mn |
| Sep 30, 2020 | 1.91 Mn |
| Jun 30, 2020 | 1.06 Mn |
| Mar 31, 2020 | 377,000.00 |